LNAI Stock Forecast: Lunai Bioworks, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 27 of 100 as at 31 Oct 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Lunai Bioworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LNAI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LNAI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
LNAI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LNAI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Lunai Bioworks, Inc. returned −97.9% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
LNAI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 16.0×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 9% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 100.0%
- Operating margin
- —
- Net margin
- —
Higher than 99% of US stocks
- Return on equity
- —
- Return on assets
- −54.1%
- Dividend yield
- —
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lunai Bioworks, Inc. has a market value of $830K and an enterprise value of $606K.
Revenue in the twelve months to 31 Mar 2026: $21K.
Net income over the same four quarters: −$128.3M, a −612568.1% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$5.3M.
Lunai Bioworks, Inc. employs 12 people — $2K of revenue per employee.
Data provided by Twelve Data
LNAI and its peers
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| LNAILunai Bioworks, Inc. | $829,677.00 | 27 |
| SLXNSilexion Therapeutics Corp. | $830,400.00 | 28 |
| MTNBMatinas BioPharma Holdings, Inc. | $890,700.00 | 39 |
| KPTIKaryopharm Therapeutics, Inc. | $901,700.00 | — |
| BBLGBone Biologics Corp. | $910,000.00 | 37 |
| GOVXGeoVax Labs, Inc. | $985,500.00 | 31 |
| OGENOragenics, Inc. | $680,800.00 | 25 |
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Lunai Bioworks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LNAI
How does Ticker Nerd's model rank LNAI?
As at 31 Oct 2026, Lunai Bioworks, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
What is the LNAI stock forecast for 2030?
No analyst covering Lunai Bioworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNAI are extrapolating price history, which says nothing about the business.
How has LNAI stock performed over the past year?
Lunai Bioworks, Inc. returned -97.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Lunai Bioworks, Inc. do?
Lunai Bioworks Inc. is a pre-clinical biotechnology company focused on developing medicines, diagnostics, and biodefense solutions. The company works across cancer, infectious disease, and precision medicine through genetically modified cell and immune-therapy platforms, including allogeneic dendritic cell vaccine programs for solid tumors such as pancreatic and breast cancers.
About Lunai Bioworks, Inc.
Lunai Bioworks Inc. is a pre-clinical biotechnology company focused on developing medicines, diagnostics, and biodefense solutions. The company works across cancer, infectious disease, and precision medicine through genetically modified cell and immune-therapy platforms, including allogeneic dendritic cell vaccine programs for solid tumors such as pancreatic and breast cancers. Its business also includes AI-enabled diagnostics and multi-omics analytics designed to support early cancer detection and recurrence monitoring by identifying individual biomarkers, including in asymptomatic patients. Through its operating segments, Lunai Bioworks combines computational biology, experimental biology, and data-driven platforms to advance therapeutic discovery and improve clinical decision-making. The company is headquartered in Los Angeles, California, and serves healthcare-related markets in the United States and the Netherlands.
CEO Mr. David H. Weinstein · 12 employees · United States · https://www.lunaibioworks.com